Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers includ ...

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like JAKK, GDOT, SIG, ROCK and PFE hold promise.

Two drugs. Two strategies. One industry in the middle of a rewiring.

Ireland’s economy grew three times as rapidly as first estimated in the first quarter. That was driven by stockpiling of ...

Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dystrophy care, targeting broader ages and mutations. We are witnessing the fastest pivot in rare-disease ...

The digital pharmaceutical supply chain management market is projected to grow at a CAGR of 9% from 2025 to 2030. The growth ...

When it rebranded as WW, it looked like the writing was on the wall for WeightWatchers. BBD Perfect Storm Health’s Nick ...

Meanwhile, the MHRA has also warned all people seeking treatment with the so-called "skinny jabs" to beware of counterfeit ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

With volatility begetting opportunity, here are all six stocks I've bought through the first five months of 2025. Image ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...